BioCryst Pharmaceuticals (NASDAQ:BCRX) versus Icosavax (NASDAQ:ICVX) Financial Analysis

Icosavax (NASDAQ:ICVXGet Free Report) and BioCryst Pharmaceuticals (NASDAQ:BCRXGet Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Icosavax and BioCryst Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Icosavax 0 2 1 0 2.33
BioCryst Pharmaceuticals 0 0 8 0 3.00

Icosavax currently has a consensus target price of $26.50, suggesting a potential upside of 71.97%. BioCryst Pharmaceuticals has a consensus target price of $13.63, suggesting a potential upside of 128.99%. Given BioCryst Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe BioCryst Pharmaceuticals is more favorable than Icosavax.

Insider and Institutional Ownership

92.6% of Icosavax shares are owned by institutional investors. Comparatively, 91.5% of BioCryst Pharmaceuticals shares are owned by institutional investors. 30.6% of Icosavax shares are owned by insiders. Comparatively, 4.4% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Icosavax has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, BioCryst Pharmaceuticals has a beta of 1.91, suggesting that its share price is 91% more volatile than the S&P 500.

Valuation & Earnings

This table compares Icosavax and BioCryst Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Icosavax $580,000.00 1,330.84 -$91.76 million ($2.22) -6.94
BioCryst Pharmaceuticals $270.83 million 4.50 -$247.12 million ($1.25) -4.76

Icosavax has higher earnings, but lower revenue than BioCryst Pharmaceuticals. Icosavax is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Icosavax and BioCryst Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Icosavax N/A -43.06% -39.53%
BioCryst Pharmaceuticals -74.43% N/A -39.26%

Summary

BioCryst Pharmaceuticals beats Icosavax on 9 of the 14 factors compared between the two stocks.

About Icosavax

(Get Free Report)

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases through virus-like particle (VLP) platform technology. Its lead product candidate IVX-A12, a respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine. The company also develops IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; and IVX-241, a vaccine candidate with hMPV target. Icosavax, Inc. was incorporated in 2017 and is headquartered in Seattle, Washington.

About BioCryst Pharmaceuticals

(Get Free Report)

BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor for complement-mediated diseases; and Galidesivir, to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.